^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Lung Cancer
    Drug:serclutamab talirine (ABBV-321) (DNA replication inhibitor, EGFR-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

    Excerpt:
    ABBV-321 is broadly active in still other EGFR-expressing solid tumor, including lung and head & neck, PDX models. Efficacy was compared across a panel of 18 PDX models with a single dosing regimen of either ABBV-321 (0.6 mg/kg, every seven days ×6) or ABBV-221 (6 mg/kg, every seven days ×6).
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-20-0149